BD Raises FY Profit Floor to $12.62, Q3 Beats Across the Board
BDX sits 39% above its 52-week low of $127.536 on light trading volume (0.2× avg).
Summary
BD lifted the lower end of its full-year adjusted EPS guidance to $12.62 from $12.52, now expecting $12.62-$12.72, after Q3 adjusted EPS of $3.23 beat the $3.14 consensus and revenue of $4.98B topped estimates. The raise reflects strength in drug delivery devices and surgical equipment. Management flagged oil price risk—resins are ~5% of COGS, and higher oil could add $60M-$70M in costs—but said price increases are already underway to offset it. FY27 revenue growth is seen starting from a low-single-digit baseline, a conservative posture. Shares rose 4% in early trading. This follows the earlier dpa-AFX report that highlighted a 34% GAAP profit drop; the adjusted beat and guidance raise provide a more complete picture.
At the time of this announcement, BDX was trading at $176.69 on NYSE in the Life Sciences sector, with a market capitalization of approximately $48.7B. The 52-week trading range was $127.54 to $187.35. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.